DDrare: Database of Drug Development for Rare Diseases

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-FDG; 68Ga-FAPI; Abatacept; Afucosylated IgG1 kappa monoclonal antibody; Belimumab; Corticosteroids; Device: Mayo Interactive Breath Hold Monitor; Drug free, IS monotherapy and GC combined with IS; Extra blood draw samples; Glucocorticoids; INEBILIZUMAB; Inebilizumab; Leflunomide; Lenalidomide; MONITOR; Methionine; Mycophenolate; Mycophenolate mofetil; Perflubutane; Prednisolone; Prednisone; Prednisone and Belimumab; Prednisone and Mycophenolate mofetil; Procedure: biliary stent; Rilzabrutinib; Rituximab; T 614; Thalidomide; XMAB5871; XmAb5871; Zanubrutinib; Zanubrutinib 80 MG; [XmAb5871]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000022633	2016/06/06	06/06/2016	Efficacy and safety of low-dose steroid treatment in asymptomatic patients with autoimmune pancreatitis.		autoimmune pancreatitis	Steroid treatment (total 56 weeks) Induction ~ 4 weeks : Prednisolone 10mg/day 4 weeks ~ 48 weeks : Prednisolone 5mg/day 48 weeks ~ 52 weeks : Prednisolone 2.5mg/day 52 weeks ~ 56 weeks : Prednisolone 1mg/day	Osaka University	NULL	Pending	20years-old	Not applicable	Male and Female	20	Not selected	Japan
2	JPRN-UMIN000003804	2010/05/01	25/06/2010	Randomized controlled trial which examines whether resuming steroid can prevent clinical relapse in the patients with asymptomatic high levels of serum IgG after ceasing steroid therapy for autoimmune pancreatitis		autoimmune pancreatitis	Prednisolone at a dose of 10mg/day is started. The dose is taperd by 2.5mg every 8-10 weeks until reaching 5mg/day. Maintenance therapy at a dose of 5 mg/day is continued. Resuming or increasing prednisolone is not planned. Patients during the course of tapering prednisolone continue to taper the dose until its complete cessation.	Department of Gastroenterology, University of Tokyo	NULL	Recruiting	20years-old	Not applicable	Male and Female	20	Not applicable	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-UMIN000022633

2016/06/06

06/06/2016

Efficacy and safety of low-dose steroid treatment in asymptomatic patients with autoimmune pancreatitis.

autoimmune pancreatitis

Steroid treatment (total 56 weeks)

Induction ~ 4 weeks : Prednisolone 10mg/day
4 weeks ~ 48 weeks : Prednisolone 5mg/day
48 weeks ~ 52 weeks : Prednisolone 2.5mg/day
52 weeks ~ 56 weeks : Prednisolone 1mg/day

Osaka University

NULL

Pending

20years-old

Not applicable

Male and Female

Not selected

Japan

JPRN-UMIN000003804

2010/05/01

25/06/2010

Randomized controlled trial which examines whether resuming steroid can prevent clinical relapse in the patients with asymptomatic high levels of serum IgG after ceasing steroid therapy for autoimmune pancreatitis

autoimmune pancreatitis

Prednisolone at a dose of 10mg/day is started. The dose is taperd by 2.5mg every 8-10 weeks until reaching 5mg/day.
Maintenance therapy at a dose of 5 mg/day is continued.
Resuming or increasing prednisolone is not planned. Patients during the course of tapering prednisolone continue to taper the dose until its complete cessation.

Department of Gastroenterology, University of Tokyo

NULL

Recruiting

20years-old

Not applicable

Male and Female

Not applicable

Japan